Date: 2015-06-08
Type of information: Opening of new premises
Compound:
Company: Hemofarm (Serbia) Stada (Germany)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On June 8, 2015, Stada\'s Serbian subsidiary Hemofarm celebrated the opening of a state-of-the-art production and filling facility for ampoules in Vršac on Sunday, May 31, 2015. Stada has thus invested a total of approximately € 150 million in Serbia since the integration of the largest Serbian health company into the Group in 2006. The value of the new plant amounts to € 4.37 million. In the future, up to 75 million ampoules will be produced annually across a floor area of 600 square meters. They are not intended for the Serbian home market only, but will be mostly exported. All production steps, from manufacturing to packaging the solutions, are carried out on site through 50 highly qualified employees.
Financial terms:
Latest news:
